摘要
Abstract
Objective To evaluate the diagnostic and prognostic utility of serum cytokeratin fragment:CK19-2G2, CyFra21-1 level and EBV VCA-IgA, EA-IgA titers in patients with nasopharyngeal squamous cell carcinoma. Methods 72 cases of normal volunteers and 47 cases of patients with undifferentiated nasopharyngeal squamous cell carcinoma before radiotherapy (pre-RT) were detected by serum CK19-2G2 (Tongsheng Shidai, Beijing), CyFra21-1 (Roche diagnosis) level and EBV VCA-IgA/EA-IgA titers (immunoenzyme technique). Results The positive rate of CK19-2G2, CyFra21-1 and EBV VCA-IgA/EA-IgA in undifferentiated nasopharyngeal squamous cell carcinoma patients were:32.69%, 46.15%, 98.08%and 71.15%, respectively;The positive rate of the above four tests in normal volunteers was: 9.32%, 9.72%, 16.67% and 0, respectively, P <0.01. The correlation of the four tests and pathological staging were statistically analyzed, Kappa value was: 0.355, 0.418, 0.78 and 0.76, χ2: 69.04, 28.21, 90.36 and 70.49, respectively, P <0.01. The positive rate of undifferentiated nasopharyngeal squamous cell carcinoma patients reduced after radiotherapy (post-RT), followed by the mass reduced. Conclusions Serum CK19-2G2 and CyFra21-1 level have significant difference between undifferentiated nasopharyngeal squamous cell carcinoma patients and the normal control. EBV VCA-IgA/EA-IgA titer detection have higher accuracy in serological diagnosis of nasopharyngeal carcinoma. Serum CK19-2G2 and CyFra21-1 level will be the valuable prognostic prediction factors of undifferentiated nasopharyngeal squamous cell carcinoma.关键词
鼻咽癌/细胞角蛋白/EB病毒VCA-IgA/EA-IgAKey words
Undifferentiated nasopharyngeal squamous cell carcinoma/Cytokeratin/EBV VCA-IgA/EA-IgA分类
医药卫生
